{"id":8914,"date":"2018-01-26T11:20:54","date_gmt":"2018-01-26T16:20:54","guid":{"rendered":"http:\/\/www.parkinson.ca\/mise-a-jour-sur-un-medicament-apomorphine-movapo\/"},"modified":"2018-01-31T16:18:10","modified_gmt":"2018-01-31T21:18:10","slug":"mise-a-jour-sur-un-medicament-apomorphine-movapo","status":"publish","type":"post","link":"https:\/\/archiveparkinson.thedev.ca\/fr\/mise-a-jour-sur-un-medicament-apomorphine-movapo\/","title":{"rendered":"Mise \u00e0 jour sur un m\u00e9dicament \u2013 Apomorphine (Movapo)"},"content":{"rendered":"<p>Nous avons le plaisir de vous informer que l\u2019apomorphine (MOVAPO) a fait l\u2019objet d\u2019une recommandation positive de la part de l\u2019Agence canadienne des m\u00e9dicaments et des technologies de la sant\u00e9 (ACMTS). Parkinson Canada a d\u00e9pos\u00e9 un formulaire \u00ab\u00a0Pr\u00e9sentation de preuves des patients\u00a0\u00bb en vue du processus d\u2019examen. Cette pr\u00e9sentation repose sur un sondage r\u00e9alis\u00e9 aupr\u00e8s de quelque 900 personnes atteintes de la maladie de Parkinson et d\u2019aidants, ainsi que sur des entrevues avec des personnes qui prennent de l\u2019apormorphine en Europe. Voici le rapport de recommandation complet (en anglais seulement) de l\u2019ACMTS :<\/p>\n<p><a href=\"https:\/\/cadth.ca\/fr\/apomorphine\">https:\/\/cadth.ca\/fr\/apomorphine<\/a><\/p>\n<p>Une recommandation positive signifie que l\u2019ACMTS recommande que les r\u00e9gimes publics d\u2019assurance-m\u00e9dicaments des provinces couvrent le co\u00fbt du m\u00e9dicament (sous conditions) :<\/p>\n<p><strong>CHLORHYDRATE D\u2019APOMORPHINE (MOVAPO\u00a0\u2013\u00a0PALADIN LABS INC.) <\/strong><\/p>\n<p>Indication : maladie de Parkinson<\/p>\n<p><strong>\u00a0<\/strong><strong>RECOMMANDATION <\/strong><\/p>\n<p>Le Comit\u00e9 canadien d\u2019expertise sur les m\u00e9dicaments de l\u2019ACMTS recommande que le chlorhydrate d\u2019apomorphine (apomorphine) soit rembours\u00e9 pour le traitement d\u2019urgence, intermittent, de crises d\u2019hypomobilit\u00e9 \u00ab hors dose \u00bb (crises en \u00ab\u00a0fin de dose\u00a0\u00bb et crises impr\u00e9visibles \u00ab\u00a0on-off\u00a0\u00bb) chez les patients qui\u00a0 sont \u00e0 un stade avanc\u00e9 de la maladie de Parkinson si les conditions et crit\u00e8res suivants sont satisfaits :<\/p>\n<p><strong>\u00a0<\/strong><strong>Crit\u00e8re <\/strong><\/p>\n<ul>\n<li>L\u2019apomorphine doit \u00eatre utilis\u00e9e uniquement comme traitement d\u2019appoint chez les patients qui re\u00e7oivent un traitement optimis\u00e9 (l\u00e9vodopa et d\u00e9riv\u00e9s et agonistes dopaminergiques) et qui sont toujours aux prises avec des crises \u00ab off \u00bb.<\/li>\n<\/ul>\n<p><strong>Conditions <\/strong><\/p>\n<ul>\n<li>Les patients trait\u00e9s avec l\u2019apomorphine doivent \u00eatre confi\u00e9s \u00e0 un m\u00e9decin ayant de l\u2019exp\u00e9rience dans le diagnostic et la prise en charge de la maladie de Parkinson.<\/li>\n<li>R\u00e9duction du prix<\/li>\n<\/ul>\n<p>Il s\u2019agit d\u2019une \u00e9tape positive et n\u00e9cessaire pour donner un acc\u00e8s \u00e9quitable au m\u00e9dicament aux personnes atteintes de la maladie de Parkinson qui en b\u00e9n\u00e9ficieraient; il s\u2019agit toutefois du d\u00e9but du processus.<\/p>\n<p>Veuillez ne pas apporter de changements \u00e0 votre r\u00e9gime th\u00e9rapeutique sans en avoir d\u2019abord discut\u00e9 avec un professionnel de la sant\u00e9. N\u2019oubliez pas que votre m\u00e9decin ou votre pharmacien peut vous aider \u00e0 g\u00e9rer votre prise de m\u00e9dicaments.<\/p>\n<p>Parkinson Canada continuera de surveiller la disponibilit\u00e9 de l\u2019apomorphine et communiquera les mises \u00e0 jour d\u00e8s qu\u2019elles seront disponibles. Si vous avez des questions au sujet de ce processus ou d\u2019autres questions touchant la communaut\u00e9 Parkinson, communiquez avec l\u2019\u00e9quipe de d\u00e9fense des int\u00e9r\u00eats de Parkinson Canada par t\u00e9l\u00e9phone au 1\u00a0800 565-3000, poste 3501, ou par courriel \u00e0 <a href=\"mailto:advocacy@parkinson.ca\">advocacy@parkinson.ca<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nous avons le plaisir de vous informer que l\u2019apomorphine (MOVAPO) a fait l\u2019objet d\u2019une recommandation positive de la part de &#8230; <a href=\"https:\/\/archiveparkinson.thedev.ca\/fr\/mise-a-jour-sur-un-medicament-apomorphine-movapo\/\" class=\"more-link\">En savoir plus<\/a><\/p>\n","protected":false},"author":90,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[64],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Mise \u00e0 jour sur un m\u00e9dicament \u2013 Apomorphine (Movapo) - Parkinson Canada<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mise \u00e0 jour sur un m\u00e9dicament \u2013 Apomorphine (Movapo) - Parkinson Canada\" \/>\n<meta property=\"og:description\" content=\"Nous avons le plaisir de vous informer que l\u2019apomorphine (MOVAPO) a fait l\u2019objet d\u2019une recommandation positive de la part de ... En savoir plus\" \/>\n<meta property=\"og:url\" content=\"https:\/\/archiveparkinson.thedev.ca\/fr\/mise-a-jour-sur-un-medicament-apomorphine-movapo\/\" \/>\n<meta property=\"og:site_name\" content=\"Parkinson Canada\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/parkinsoncanada\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-01-26T16:20:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-01-31T21:18:10+00:00\" \/>\n<meta name=\"author\" content=\"Sally Adam\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ParkinsonCanada\" \/>\n<meta name=\"twitter:site\" content=\"@ParkinsonCanada\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sally Adam\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/archiveparkinson.thedev.ca\/fr\/mise-a-jour-sur-un-medicament-apomorphine-movapo\/\",\"url\":\"https:\/\/archiveparkinson.thedev.ca\/fr\/mise-a-jour-sur-un-medicament-apomorphine-movapo\/\",\"name\":\"Mise \u00e0 jour sur un m\u00e9dicament \u2013 Apomorphine (Movapo) - Parkinson Canada\",\"isPartOf\":{\"@id\":\"https:\/\/archiveparkinson.thedev.ca\/#website\"},\"datePublished\":\"2018-01-26T16:20:54+00:00\",\"dateModified\":\"2018-01-31T21:18:10+00:00\",\"author\":{\"@id\":\"https:\/\/archiveparkinson.thedev.ca\/#\/schema\/person\/c0fae11b7726599d21fc7e259f599b6c\"},\"breadcrumb\":{\"@id\":\"https:\/\/archiveparkinson.thedev.ca\/fr\/mise-a-jour-sur-un-medicament-apomorphine-movapo\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/archiveparkinson.thedev.ca\/fr\/mise-a-jour-sur-un-medicament-apomorphine-movapo\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/archiveparkinson.thedev.ca\/fr\/mise-a-jour-sur-un-medicament-apomorphine-movapo\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/archiveparkinson.thedev.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mise \u00e0 jour sur un m\u00e9dicament \u2013 Apomorphine (Movapo)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/archiveparkinson.thedev.ca\/#website\",\"url\":\"https:\/\/archiveparkinson.thedev.ca\/\",\"name\":\"Parkinson Canada\",\"description\":\"Empowering the Parkinson&#039;s community across Canada\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/archiveparkinson.thedev.ca\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/archiveparkinson.thedev.ca\/#\/schema\/person\/c0fae11b7726599d21fc7e259f599b6c\",\"name\":\"Sally Adam\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/archiveparkinson.thedev.ca\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e128593d647758f8c89e39328020dc8b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e128593d647758f8c89e39328020dc8b?s=96&d=mm&r=g\",\"caption\":\"Sally Adam\"},\"sameAs\":[\"http:\/\/parkinson.ca\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mise \u00e0 jour sur un m\u00e9dicament \u2013 Apomorphine (Movapo) - Parkinson Canada","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Mise \u00e0 jour sur un m\u00e9dicament \u2013 Apomorphine (Movapo) - Parkinson Canada","og_description":"Nous avons le plaisir de vous informer que l\u2019apomorphine (MOVAPO) a fait l\u2019objet d\u2019une recommandation positive de la part de ... En savoir plus","og_url":"https:\/\/archiveparkinson.thedev.ca\/fr\/mise-a-jour-sur-un-medicament-apomorphine-movapo\/","og_site_name":"Parkinson Canada","article_publisher":"https:\/\/www.facebook.com\/parkinsoncanada\/","article_published_time":"2018-01-26T16:20:54+00:00","article_modified_time":"2018-01-31T21:18:10+00:00","author":"Sally Adam","twitter_card":"summary_large_image","twitter_creator":"@ParkinsonCanada","twitter_site":"@ParkinsonCanada","twitter_misc":{"\u00c9crit par":"Sally Adam","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/archiveparkinson.thedev.ca\/fr\/mise-a-jour-sur-un-medicament-apomorphine-movapo\/","url":"https:\/\/archiveparkinson.thedev.ca\/fr\/mise-a-jour-sur-un-medicament-apomorphine-movapo\/","name":"Mise \u00e0 jour sur un m\u00e9dicament \u2013 Apomorphine (Movapo) - Parkinson Canada","isPartOf":{"@id":"https:\/\/archiveparkinson.thedev.ca\/#website"},"datePublished":"2018-01-26T16:20:54+00:00","dateModified":"2018-01-31T21:18:10+00:00","author":{"@id":"https:\/\/archiveparkinson.thedev.ca\/#\/schema\/person\/c0fae11b7726599d21fc7e259f599b6c"},"breadcrumb":{"@id":"https:\/\/archiveparkinson.thedev.ca\/fr\/mise-a-jour-sur-un-medicament-apomorphine-movapo\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/archiveparkinson.thedev.ca\/fr\/mise-a-jour-sur-un-medicament-apomorphine-movapo\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/archiveparkinson.thedev.ca\/fr\/mise-a-jour-sur-un-medicament-apomorphine-movapo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/archiveparkinson.thedev.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Mise \u00e0 jour sur un m\u00e9dicament \u2013 Apomorphine (Movapo)"}]},{"@type":"WebSite","@id":"https:\/\/archiveparkinson.thedev.ca\/#website","url":"https:\/\/archiveparkinson.thedev.ca\/","name":"Parkinson Canada","description":"Empowering the Parkinson&#039;s community across Canada","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/archiveparkinson.thedev.ca\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/archiveparkinson.thedev.ca\/#\/schema\/person\/c0fae11b7726599d21fc7e259f599b6c","name":"Sally Adam","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/archiveparkinson.thedev.ca\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e128593d647758f8c89e39328020dc8b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e128593d647758f8c89e39328020dc8b?s=96&d=mm&r=g","caption":"Sally Adam"},"sameAs":["http:\/\/parkinson.ca"]}]}},"_links":{"self":[{"href":"https:\/\/archiveparkinson.thedev.ca\/fr\/wp-json\/wp\/v2\/posts\/8914"}],"collection":[{"href":"https:\/\/archiveparkinson.thedev.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/archiveparkinson.thedev.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/archiveparkinson.thedev.ca\/fr\/wp-json\/wp\/v2\/users\/90"}],"replies":[{"embeddable":true,"href":"https:\/\/archiveparkinson.thedev.ca\/fr\/wp-json\/wp\/v2\/comments?post=8914"}],"version-history":[{"count":0,"href":"https:\/\/archiveparkinson.thedev.ca\/fr\/wp-json\/wp\/v2\/posts\/8914\/revisions"}],"wp:attachment":[{"href":"https:\/\/archiveparkinson.thedev.ca\/fr\/wp-json\/wp\/v2\/media?parent=8914"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/archiveparkinson.thedev.ca\/fr\/wp-json\/wp\/v2\/categories?post=8914"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/archiveparkinson.thedev.ca\/fr\/wp-json\/wp\/v2\/tags?post=8914"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}